‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment-Reference-Cited by-同舟云学术

‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment

Published:2018-09-12 Issue:1 Volume:18 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Rotman J.,Mom C. H.^ORCID,Jordanova E. S.,de Gruijl T. D.,Kenter G. G.

Funder

Stichting VUmc Cancer Center Amsterdam

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-018-4764-0.pdf

Reference46 articles.

1. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(Suppl. 1):4–15.

2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. https://doi.org/10.1002/ijc.29210 .

3. Integraal Kankercentrum Nederland: IKNL. http://www.cijfersoverkanker.nl (2011–2017). Accessed 6 Sept 2017.

4. Maine D, Hurlburt S, Greeson D. Cervical Cancer prevention in the 21st century: cost is not the only issue. Am J Public Health. 2011;101:1549–55. https://doi.org/10.2105/AJPH.2011.300204 .

5. Takeda N, Sakuragi N, Takeda M, Okamoto K, Kuwabara M, Negishi H, et al. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand. 2002;81:1144–51. https://doi.org/10.1034/j.1600-0412.2002.811208.x .

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel technologies for applying immune checkpoint blockers;International Review of Cell and Molecular Biology;2024

2. Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer;Scientific Reports;2023-12-19

3. Advances in immunotherapy for gynecological malignancies;Critical Reviews in Oncology/Hematology;2023-08

4. Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies;Biomedicine & Pharmacotherapy;2023-06

5. Chemo-immunoablation of solid tumors: A new concept in tumor ablation;Frontiers in Immunology;2023-01-12